Novavax, Inc. (NVAX): Price and Financial Metrics

Novavax, Inc. (NVAX): $203.33

-18.17 (-8.20%)

POWR Rating

Component Grades













Add NVAX to Watchlist
Sign Up

Industry: Biotech


of 493

in industry

NVAX Stock Summary

  • NVAX's price/sales ratio is 34.4; that's higher than the P/S ratio of 93.16% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Novavax Inc is reporting a growth rate of 238.52%; that's higher than 93.55% of US stocks.
  • As for revenue growth, note that NVAX's revenue has grown 2,448.48% over the past 12 months; that beats the revenue growth of 99.59% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Novavax Inc are ANAB, XNCR, CARA, MORF, and CNCE.
  • NVAX's SEC filings can be seen here. And to visit Novavax Inc's official web site, go to

NVAX Stock Price Chart Interactive Chart >

Price chart for NVAX

NVAX Price/Volume Stats

Current price $203.33 52-week high $331.68
Prev. close $221.50 52-week low $16.41
Day low $200.01 Volume 1,579,360
Day high $222.32 Avg. volume 4,145,415
50-day MA $215.86 Dividend yield N/A
200-day MA $145.47 Market Cap 15.02B

Novavax, Inc. (NVAX) Company Bio

Novavax, Inc. focuses on discovering, developing, and commercializing recombinant nanoparticle vaccines and adjuvants. The company was founded in 1987 and is based in Gaithersburg, Maryland.

NVAX Latest News Stream

Event/Time News Detail
Loading, please wait...

NVAX Latest Social Stream

Loading social stream, please wait...

View Full NVAX Social Stream

Latest NVAX News From Around the Web

Below are the latest news stories about Novavax Inc that investors may wish to consider to help them evaluate NVAX as an investment opportunity.

15 Best Stocks in the Past Week: Vaccine Stocks Surge Higher - TheStreet

The best-performing stocks in the past week include Novavax, BioNTech, Moderna, Nuance, Nvidia, Wells Fargo, Tesla, Dell, and more.

The Street | April 18, 2021

Novavax Is Missing Out on a Big Deal

Novavax (NASDAQ: NVAX) hasn't set up a supply agreement for its coronavirus vaccine with the EU. In this video from Motley Fool Live, recorded on March 29, contributors Brian Orelli and Keith Speights discuss what might be taking so long and why this is truly a bid deal for Novavax. Brian Orelli: Moving on to Novavax, according to Reuters, the company is having some issues sourcing raw materials for its COVID-19 vaccine, which is causing it to delay setting up supply agreements with the European Union.

Yahoo | April 17, 2021

Moderna cuts UK COVID vaccine deliveries as pregnant women told mRNA jabs are safe

The Moderna jab, which works in a similar way to the Pfizer vaccine, uses synthetic messenger RNA (mRNA) technology that can be quickly tweaked to address new mutations of a virus.

Yahoo | April 17, 2021

The push to vaccinate farm workers against COVID-19

Teresa Romero, United Farm Workers President, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss vaccinations for farm workers and immigration issues.

Yahoo | April 16, 2021

Vaccinating kids will be very important in getting to herd immunity: Expert

Kristen Choi, PhD, MS, RN, Assistant Professor, UCLA School of Nursing, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss the latest on the coronavirus.

Yahoo | April 16, 2021

Read More 'NVAX' Stories Here

NVAX Price Returns

1-mo -10.92%
3-mo 62.60%
6-mo 117.26%
1-year 754.33%
3-year 494.53%
5-year 84.85%
YTD 82.34%
2020 2,701.76%
2019 -89.18%
2018 48.39%
2017 -1.59%
2016 -84.98%

Continue Researching NVAX

Want to see what other sources are saying about Novavax Inc's financials and stock price? Try the links below:

Novavax Inc (NVAX) Stock Price | Nasdaq
Novavax Inc (NVAX) Stock Quote, History and News - Yahoo Finance
Novavax Inc (NVAX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.1143 seconds.